Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
DSIP
Also known as: Delta Sleep-Inducing Peptide, Delta Sleep Peptide
DSIP is a nine-amino acid neuropeptide first isolated from rabbit brain in 1977 during induced sleep. Despite its name, its role in sleep induction remains controversial, with inconsistent results across studies. It has been investigated for stress modulation, pain relief, alcohol and opioid withdrawal, and sleep normalization. Research interest has waned since the 1990s.
Risk Level
Medium RiskDifficulty
Intermediate| CAS Number | 62568-57-4 |
| Molecular Formula | C35H48N10O15 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Mechanism is not fully elucidated. Appears to modulate GABA and glutamate receptor function, influence cortisol and ACTH secretion, and normalize disrupted circadian rhythms. May act more as a sleep normalizer than a sleep inducer, restoring physiological sleep architecture rather than forcing sedation.
Dosing Research
Underground protocols: 100-300 mcg subcutaneously or intramuscularly before bedtime. Some protocols use every other day or 5 days on/2 days off. Clinical studies used 25-30 nmol/kg intravenously. Peptide is relatively unstable and requires careful storage.
Side Effects & Risks
Limited adverse event data. Some users report morning grogginess, vivid dreams, or paradoxical insomnia. No serious adverse events documented in the small number of clinical studies conducted. Long-term safety is unknown.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.